Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad Financials Overview

Financials in millions MYR. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	929.41	931.69	813.7	704.73	696.72	639.18
Revenue Growth	4.79%	14.50%	15.46%	1.15%	9.00%	12.16%
Gross Profit Gross Profit Growth	383.56	363.14	301.54	268.33	279.82	253.98
Operating Income Operating Income Growth	151.99	133.78	100.26	78.71	92.91	88.77
Net Income Net Income Growth	102.21	87.46	62.65	52.65	70.11	65.68
Earnings Per Share EPS Growth	0.11	0.09	0.07	0.05	0.07	0.07
EPS Growth	33.38%	39.62%	18.57%	-25.71%	4.50%	12.05%

Revenue by Geography

Chart

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Malaysia Malaysia Growth	871.83	754.18	650.55	654.89	596.89
Export Export Growth	59.87	59.51	54.18	41.83	42.29
Total Total Growth	931.69	813.7	704.73	696.72	639.18

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	255.99	290.87	264.55	270.5	157.64	137.98
Total Debt Total Debt Growth	474.08	496.08	515.82	548.85	431.6	403.84
Net Cash (Debt) Net Cash Growth	-218.09	-205.21	-251.28	-278.35	-273.97	-265.86
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-0.23	-0.21	-0.26	-0.29	-0.29	-0.29

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	82.86	106.83	83.34	48.8	70.27	43.2
Capital Expenditures CapEx Growth	-18.34	-26.84	-23.57	-32.95	-65.18	-109.36
Free Cash Flow Free Cash Flow Growth	64.52	79.99	59.77	15.86	5.08	-66.16
Free Cash Flow Growth	-35.01%	33.83%	276.91%	211.98%	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	41.27%	38.98%	37.06%	38.07%	40.16%	39.74%
Operating Margin	16.35%	14.36%	12.32%	11.17%	13.33%	13.89%
Pretax Margin	14.45%	12.33%	9.83%	8.98%	12.18%	12.98%
Profit Margin	11.00%	9.39%	7.70%	7.47%	10.06%	10.28%
FCF Margin	6.94%	8.59%	7.35%	2.25%	0.73%	-10.35%

Dividends

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 1, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Dividend Per Share Dividend Per Share Growth	0.045	0.045	0.030	0.023	0.023	0.022
Dividend Per Share Growth	30.00%	51.67%	30.44%	0%	5.75%	-55.43%
Dividend Yield	3.67%	3.72%	2.52%	1.96%	1.56%	1.44%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 1, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	12.05	13.75	19.19	23.02	21.87	24.09
Forward PE	11.62	12.08	14.74	14.77	15.91	20.97
P/FCF Ratio	19.08	15.03	20.12	76.43	301.61	-
PS Ratio	1.32	1.29	1.48	1.72	2.20	2.48

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 28, 2026

Data Sources Report a data error